Teleflex(TFX)

Search documents
Teleflex Investor News: Rosen Law Firm Encourages Teleflex Incorporated Investors to Inquire About Securities Class Action Investigation - TFX
Prnewswire· 2025-05-01 23:48
NEW YORK, May 1, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Teleflex Incorporated (NYSE: TFX) resulting from allegations that Teleflex may have issued materially misleading business information to the investing public.So What: If you purchased Teleflex securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. Th ...
TFX Investors Have Opportunity to Join Teleflex Incorporated Fraud Investigation with the Schall Law Firm
Prnewswire· 2025-05-01 20:36
LOS ANGELES, May 1, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Teleflex Incorporated ("Teleflex" or "the Company") (NYSE: TFX) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Teleflex is the subject of an article published by Fierce Biotech on February 27 ...
Here's What Key Metrics Tell Us About Teleflex (TFX) Q1 Earnings
ZACKS· 2025-05-01 14:35
For the quarter ended March 2025, Teleflex (TFX) reported revenue of $700.67 million, down 5% over the same period last year. EPS came in at $2.91, compared to $3.21 in the year-ago quarter.The reported revenue represents a surprise of +0.22% over the Zacks Consensus Estimate of $699.13 million. With the consensus EPS estimate being $2.88, the EPS surprise was +1.04%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expect ...
Teleflex (TFX) Tops Q1 Earnings and Revenue Estimates
ZACKS· 2025-05-01 12:50
Teleflex (TFX) came out with quarterly earnings of $2.91 per share, beating the Zacks Consensus Estimate of $2.88 per share. This compares to earnings of $3.21 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 1.04%. A quarter ago, it was expected that this medical equipment maker would post earnings of $3.86 per share when it actually produced earnings of $3.89, delivering a surprise of 0.78%.Over the last four quarters, the co ...
Teleflex(TFX) - 2025 Q1 - Earnings Call Transcript
2025-05-01 12:00
Teleflex (TFX) Q1 2025 Earnings Call May 01, 2025 08:00 AM ET Speaker0 Good morning, ladies and gentlemen, and welcome to the Teleflex First Quarter twenty twenty five Earnings Conference Call. At this time, all participants have been placed in a listen only mode. At the end of the company's prepared remarks, we will conduct a question and answer session. Please note that this conference call is being recorded, and we will be available on the company's website for replay shortly. Now I will turn the call ov ...
Teleflex(TFX) - 2025 Q1 - Earnings Call Presentation
2025-05-01 11:42
Teleflex Incorporated First Quarter 2025 Earnings Conference Call 5/1/2025 Conference Call Logistics The release, accompanying slides, and replay webcast are available online at www.teleflex.com (click on Investors) An audio replay of the call will be available beginning at 11:00 am Eastern Time on May 1, 2025 either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S.) or 1 609 800 9909 (all other locations). The confirmation code is 69028. Today's Speakers Liam ...
Teleflex(TFX) - 2025 Q1 - Quarterly Results
2025-05-01 11:00
FOR IMMEDIATE RELEASE May 1, 2025 Exhibit 99.1 First quarter financial summary 2025 guidance summary "Our performance for the first quarter was in line with our expectations" said Liam Kelly, Teleflex's Chairman, President and Chief Executive Officer. "Were it not for the impact of tariffs enacted since the issuance of our previous guidance, we project that our full-year results for 2025 would fall within our previously stated guidance ranges. We are evaluating strategies to mitigate our exposure to tariffs ...
Teleflex Reports First Quarter Financial Results and Full Year 2025 Outlook
GlobeNewswire· 2025-05-01 10:30
WAYNE, Pa., May 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the first quarter ended March 30, 2025. First quarter financial summary Revenues of $700.7 million, down 5.0% compared to the prior year period; down 3.8% on an adjusted constant currency basis GAAP diluted EPS from continuing operations of $2.07, compared to $0.33 in the prior year period Adjusted diluted EPS from continuing operations of $2.91, compared to $3.21 in the prio ...
Teleflex to Present at the BofA Securities 2025 Health Care Conference
GlobeNewswire· 2025-04-30 10:45
WAYNE, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Management of Teleflex Incorporated (NYSE: TFX), will be presenting at the BofA Securities 2025 Health Care Conference at the Encore Hotel in Las Vegas, Nevada, on Wednesday, May 14, 2025, at 1:40 p.m. (PT). A live audio webcast of the conference presentation will be available on the investor section of the Teleflex website at teleflex.com. About Teleflex IncorporatedAs a global provider of medical technologies, Teleflex is driven by our purpose to improve the ...
Teleflex receives FDA 510(k) Clearance for Expanded Indications of the QuikClot Control+™ Hemostatic Device
GlobeNewswire News Room· 2025-04-30 10:30
WAYNE, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of an expansion to the Indications for Use of the QuikClot Control+™ Hemostatic Device to include all grades of internal and external bleeding. The QuikClot Control+™ Device was previously indicated for temporary control of class III and class IV internal organ space bleeding, severely bleeding surgical w ...